参与物
| 角色 | 名称 | HCID | 投料 |
|---|
| 反应物 | 乙酰胺 | HCID 178 | — |
| 反应物 | 氢溴酸 | HCID 260 | — |
| 反应物 | 二甲醚 | HCID 8254 | — |
| 反应物 | 碘化氢 | HCID 24841 | — |
| 反应物 | 3,5-二碘-4-(4-甲氧苯氧基)-N-乙酰-L-苯丙氨酸乙酯 | HCID 10952191 | — |
| 产物 | 3,5-二碘-L-甲状腺素 | HCID 92859 | — |
反应步骤
Many patent and non-patent literature describe the use of an intermediate called Bis (p-anisyl)iodonium bromide in the preparation of Levothyroxine sodium. Hillmann (Z. Naturforch 1956; 11b:424-425) describes a process for the assembly of the biphenyl-ether system present in Levothyroxine, wherein a key coupling reaction is initiated between N-Acetyl 3,5-diiodo-L-tyrosine ethyl ester, derived from the stepwise protective conversion of amine as amide and acid as ester of 3,5 diido-L-tyrosine, and Bis (p-anisyl)iodonium bromide in the presence of copper metal or powder as a catalyst to afford (S)—N-acetyl-3,5-diiodo-4-p-methoxyphenoxyphenylalanine ethyl ester, with 87% yield. All the three protective groups in (S)—N-acetyl-3,5-diiodo-4-p-methoxyphenoxyphenylalanine ethyl ester, viz. acetamide, methyl ether, ethyl ester were cleaved using a mixture of Hydroiodic acid and Hydrobromic acid to give 3,5-Diiodothyronine. 3,5-Diiodothyronine on subsequent iodination with iodine gave L-thyroxine of an yield that corresponds to 92%.
来源与证据
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 专利号 | US09428444B2 |
|---|
| 来源数据集 | uspto-grants-2016_08 |
|---|
| ORD ID | ord-19dc8d269fa84dfbaa970919e8c7f67c |
|---|
| 来源说明 | uspto-grants-2016_08 |
|---|